DermRx.
← All drugs

deucravacitinib

Sotyktu

Modality
small molecule (oral)
Mechanism
TYK2 allosteric (pseudokinase domain) inhibitor
Targets
TYK2
Storage
room temperature
Approved
plaque psoriasis — FDA 2022
In trial
psoriatic arthritis, SLE, DLE
Pregnancy
limited data
Monitoring
TB, CBC, LFTs, lipids, triglycerides
Sources
Last verified
2026-04-14

Mechanism of action

Sotyktu label (FDA, 2022); Burke J Invest Dermatol 2023
drugtargetsignalingeffectorcellularphenotype⊣ red bar = blocked/reduced by drug